Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Cyclophosphamide in Treating Patients with Hematological Malignancies after Undergoing Donor Stem Cell Transplant

Trial Status: administratively complete

This phase II trial studies how well cyclophosphamide works in treating patients with cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system (hematological malignancies) after undergoing donor stem cell transplant. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cyclophosphamide after a donor stem cell transplant may decrease the complication rate of transplant.